Health testing with all subjects who participated in any phase I clinical study and received at least one dose of HTL0018318/AGN-242071 to date.
Completed
- Conditions
- General Health10019654
- Registration Number
- NL-OMON48060
- Lead Sponsor
- Heptares Therapeutics Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 170
Inclusion Criteria
All subjects who received at least one dose of active study medication in any prior HTL0018318/AGN-242071 clinical study.
Exclusion Criteria
None
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Liver Ultrasound<br /><br>Clinical Laboratory Assessments<br /><br>Optional genetics & biomarkers</p><br>
- Secondary Outcome Measures
Name Time Method <p>N.A.</p><br>